Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms MOCHA
- 04 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 04 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
- 14 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Nov 2018.